• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3,5-二苯甲酰基-4-(3-苯氧基苯基)-1,4-二氢-2,6-二甲基吡啶(DP7)作为一种新型多药耐药逆转剂,对血管平滑肌收缩性无影响。

3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility.

作者信息

Saponara Simona, Kawase Masami, Shah Anamik, Motohashi Noboru, Molnar Joseph, Ugocsai Katalin, Sgaragli Giampietro, Fusi Fabio

机构信息

Istituto di Scienze Farmacologiche, Università degli Studi di Siena, via A. Moro 2, 53100 Siena, Italy.

出版信息

Br J Pharmacol. 2004 Feb;141(3):415-22. doi: 10.1038/sj.bjp.0705635. Epub 2004 Jan 12.

DOI:10.1038/sj.bjp.0705635
PMID:14718255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1574217/
Abstract

The aim of this study was to investigate the effects of 3,5-diacetyl- (DP1-DP5) and 3,5-dibenzoyl-1,4-dihydropyridines (DP6-DP11) on vascular functions in vitro, by comparing their mechanical and electrophysiological actions in rat aorta rings and single rat tail artery myocytes, respectively, and to quantify their multidrug resistance (MDR)-reversing activity in L5178 Y mouse T-lymphoma cells transfected with MDR1 gene. In rat aorta, the 11 compounds tested, but 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7), 3,5-dibenzoyl-4-(3-chlorophenyl)-1,4-dihydro-2,6-dimethylpyridine (DP9), 3,5-dibenzoyl-4-(4-chlorophenyl)-1,4-dihydro-2,6-dimethylpyridine (DP10) and 3,5-dibenzoyl-4-phenyl-1,4-dihydro-2,6-dimethylpyridine (DP11), antagonized 60 mm K+ (K60)-induced contraction in a concentration-dependent manner, with IC50 (m) values ranging between 5.65 x 10(-7) and 2.23 x 10(-5). The 11 dihydropyridines tested, but DP7, inhibited L-type Ca2+ current recorded in artery myocytes in a concentration-dependent manner, with IC50 (M) values ranging between 1.12 x 10(-6) and 6.90 x 10(-5). The K+ -channel opener cromakalim inhibited the Ca2+ -induced contraction in K30 but not that evoked in K60. On the contrary, DP7 was ineffective in both experimental conditions. When the rings were preincubated with 1 mm Ni2+ plus 1 microm nifedipine, the response to phenylephrine was significantly reduced by 2,5-di-t-butyl-1,4-benzohydroquinone (BHQ), a well-known endoplasmic reticulum Ca2+ -ATPase inhibitor. DP7 had no effects on this model system. In L5178 MDR cell line, the 11 dihydropyridines tested, but 3,5-diacetyl-4-(2-nitrophenyl)-1,4-dihydro-2,6-dimethylpyridine (DP1), 3,5-diacetyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP2) and 3,5-diacetyl-4-(3-chlorophenyl)-1,4-dihydro-2,6-dimethylpyridine (DP4), exhibited an MDR-reversing activity, with IC50 values ranging between 3.02 x 10(-7) and 4.27 x 10(-5), DP7 being the most potent. In conclusion, DP7 may represent a lead compound for the development of potent dihydropyridine MDR chemosensitizers devoid of vascular effects. British Journal of Pharmacology (2004) 141, 415-422. doi:10.1038/sj.bjp.0705635

摘要

本研究旨在通过分别比较3,5 - 二乙酰基 - 1,4 - 二氢吡啶(DP1 - DP5)和3,5 - 二苯甲酰基 - 1,4 - 二氢吡啶(DP6 - DP11)在大鼠主动脉环和大鼠单尾动脉肌细胞中的力学和电生理作用,来研究它们对体外血管功能的影响,并量化它们在转染了MDR1基因的L5178Y小鼠T淋巴瘤细胞中的多药耐药(MDR)逆转活性。在大鼠主动脉中,所测试的11种化合物中,除3,5 - 二苯甲酰基 - 4 -(3 - 苯氧基苯基)- 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP7)、3,5 - 二苯甲酰基 - 4 -(3 - 氯苯基)- 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP9)、3,5 - 二苯甲酰基 - 4 -(4 - 氯苯基)- 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP10)和3,5 - 二苯甲酰基 - 4 - 苯基 - 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP11)外,均以浓度依赖性方式拮抗60 mM K⁺(K60)诱导的收缩,IC50(m)值在5.65×10⁻⁷至2.23×10⁻⁵之间。所测试的11种二氢吡啶中,除DP7外,均以浓度依赖性方式抑制动脉肌细胞中记录的L型Ca²⁺电流,IC50(M)值在1.12×10⁻⁶至6.90×10⁻⁵之间。钾通道开放剂克罗卡林抑制K30中Ca²⁺诱导的收缩,但不抑制K60中诱发的收缩。相反,DP7在两种实验条件下均无效。当主动脉环用1 mM Ni²⁺加1 μM硝苯地平预孵育时,2,5 - 二叔丁基 - 1,4 - 苯二酚(BHQ)(一种著名的内质网Ca²⁺ - ATP酶抑制剂)可显著降低对去氧肾上腺素的反应。DP7对该模型系统无影响。在L5178 MDR细胞系中,所测试的11种二氢吡啶中,除3,5 - 二乙酰基 - 4 -(2 - 硝基苯基)- 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP1)、3,5 - 二乙酰基 - 4 -(3 - 苯氧基苯基)- 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP2)和3,5 - 二乙酰基 - 4 -(3 - 氯苯基)- 1,4 - 二氢 - 2,6 - 二甲基吡啶(DP4)外,均表现出MDR逆转活性,IC50值在3.02×10⁻⁷至4.27×10⁻⁵之间,DP7最为有效。总之,DP7可能代表一种开发强效无血管效应的二氢吡啶MDR化学增敏剂的先导化合物。《英国药理学期刊》(2004年)141卷,415 - 422页。doi:10.1038/sj.bjp.0705635

相似文献

1
3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility.3,5-二苯甲酰基-4-(3-苯氧基苯基)-1,4-二氢-2,6-二甲基吡啶(DP7)作为一种新型多药耐药逆转剂,对血管平滑肌收缩性无影响。
Br J Pharmacol. 2004 Feb;141(3):415-22. doi: 10.1038/sj.bjp.0705635. Epub 2004 Jan 12.
2
3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart.3,5-二苯甲酰基-4-(3-苯氧基苯基)-1,4-二氢-2,6-二甲基吡啶(DP7):一种对Langendorff灌注大鼠心脏无影响的新型多药耐药抑制剂。
Eur J Pharmacol. 2007 Jun 1;563(1-3):160-3. doi: 10.1016/j.ejphar.2007.02.001. Epub 2007 Feb 16.
3
DP7, a novel dihydropyridine multidrug resistance reverter, shows only weak inhibitory activity on human CYP3A enzyme(s).DP7是一种新型二氢吡啶多药耐药逆转剂,对人CYP3A酶仅表现出微弱的抑制活性。
Eur J Pharmacol. 2009 Jul 1;614(1-3):7-13. doi: 10.1016/j.ejphar.2009.04.019. Epub 2009 Apr 18.
4
Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells.两种硅化合物ALIS 409和ALIS 421(癌细胞中新型多药耐药逆转剂)的血管活性。
Cancer Chemother Pharmacol. 2008 Mar;61(3):443-51. doi: 10.1007/s00280-007-0488-6. Epub 2007 Apr 27.
5
Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.与维拉帕米和阿霉素相比,评估新合成的二氢吡啶衍生物对T47D亲本细胞系和耐药细胞系的体外抗癌作用。
Cell Biol Toxicol. 2008 Apr;24(2):165-74. doi: 10.1007/s10565-007-9026-x. Epub 2007 Sep 6.
6
Effects of 2,5-di-t-butyl-1,4-benzohydroquinone (BHQ) on rat aorta smooth muscle.2,5-二叔丁基-1,4-苯二酚(BHQ)对大鼠主动脉平滑肌的影响。
Eur J Pharmacol. 1998 Apr 10;346(2-3):237-43. doi: 10.1016/s0014-2999(98)00056-9.
7
3,5-dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.3,5-二苯甲酰基-1,4-二氢吡啶:肿瘤细胞中的合成与多药耐药逆转
Bioorg Med Chem. 2002 Apr;10(4):1051-5. doi: 10.1016/s0968-0896(01)00363-7.
8
In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents.新型多药耐药逆转剂不对称N,N-双(链烷醇)胺芳基酯血管效应的体外和计算机模拟分析
Naunyn Schmiedebergs Arch Pharmacol. 2016 Sep;389(9):1033-43. doi: 10.1007/s00210-016-1266-y. Epub 2016 Jun 28.
9
Brazilein-induced contraction of rat arterial smooth muscle involves activation of Ca2+ entry and ROK, ERK pathways.巴西苏木精诱导大鼠动脉平滑肌收缩涉及钙内流以及ROK、ERK信号通路的激活。
Eur J Pharmacol. 2008 Feb 12;580(3):366-71. doi: 10.1016/j.ejphar.2007.11.012. Epub 2007 Nov 17.
10
Metamizol acts as an ATP sensitive potassium channel opener to inhibit the contracting response induced by angiotensin II but not to norepinephrine in rat thoracic aorta smooth muscle.安乃近作为一种ATP敏感性钾通道开放剂,可抑制大鼠胸主动脉平滑肌中由血管紧张素II诱导的收缩反应,但对去甲肾上腺素诱导的收缩反应无抑制作用。
Vascul Pharmacol. 2005 Aug;43(2):120-7. doi: 10.1016/j.vph.2005.05.003.

引用本文的文献

1
Evaluation of Novel Benzo-annelated 1,4-dihydropyridines as MDR Modulators in Cancer Cells.新型苯并稠合1,4-二氢吡啶作为癌细胞中多药耐药调节剂的评估
Anticancer Agents Med Chem. 2024;24(14):1047-1055. doi: 10.2174/0118715206314406240502054139.
2
Vietnamese : A Promising Source of Mono- and Bifunctional Vasodilators.越南:单功能和双功能血管扩张剂的有前途的来源。
Molecules. 2022 Jul 14;27(14):4505. doi: 10.3390/molecules27144505.
3
Design, Synthesis and Anti-Tubercular Activity of Novel 1, 4-Dihydropyrine-3, 5-Dicarboxamide Containing 4(5)-Chloro-2-Ethyl- 5(4)-Imidazolyl Moiety.含4(5)-氯-2-乙基-5(4)-咪唑基部分的新型1,4-二氢吡啶-3,5-二甲酰胺的设计、合成及抗结核活性
Iran J Pharm Res. 2016 Fall;15(4):791-799.
4
Design, Synthesis and Evaluation of Antitubercular Activity of Novel Dihydropyridine Containing Imidazolyl Substituent.含咪唑基取代基的新型二氢吡啶的抗结核活性设计、合成与评价
Iran J Pharm Res. 2015 Fall;14(4):1067-75.
5
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.一种使用分子相互作用场预测 P 糖蛋白(ABCB1)抑制作用的新方法。
J Med Chem. 2011 Mar 24;54(6):1740-51. doi: 10.1021/jm101421d. Epub 2011 Feb 22.

本文引用的文献

1
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.癫痫多药耐药性与药物转运蛋白基因ABCB1多态性的关联。
N Engl J Med. 2003 Apr 10;348(15):1442-8. doi: 10.1056/NEJMoa021986.
2
New multidrug resistance reversal agents.新型多药耐药逆转剂
Curr Drug Targets. 2003 Jan;4(1):31-43. doi: 10.2174/1389450033347064.
3
Multidrug resistance in cancer: role of ATP-dependent transporters.癌症中的多药耐药性:ATP 依赖性转运蛋白的作用
Nat Rev Cancer. 2002 Jan;2(1):48-58. doi: 10.1038/nrc706.
4
3,5-dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.3,5-二苯甲酰基-1,4-二氢吡啶:肿瘤细胞中的合成与多药耐药逆转
Bioorg Med Chem. 2002 Apr;10(4):1051-5. doi: 10.1016/s0968-0896(01)00363-7.
5
2,5-Di-t-butyl-1,4-benzohydroquinone (BHQ) inhibits vascular L-type Ca(2+) channel via superoxide anion generation.2,5-二叔丁基-1,4-苯二酚(BHQ)通过超氧阴离子生成抑制血管L型钙通道。
Br J Pharmacol. 2001 Aug;133(7):988-96. doi: 10.1038/sj.bjp.0704183.
6
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.癌症中的多药耐药性(MDR)。机制、使用MDR调节剂进行逆转以及MDR调节剂在影响抗癌药物药代动力学方面的作用。
Eur J Pharm Sci. 2000 Oct;11(4):265-83. doi: 10.1016/s0928-0987(00)00114-7.
7
Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome.风湿性自身免疫性疾病中的多药耐药性1(MDR-1)。第一部分:类风湿关节炎患者淋巴细胞中P-糖蛋白活性增加可能影响疾病转归。
Joint Bone Spine. 2000 Jan;67(1):30-9.
8
3,5-diacetyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.3,5-二乙酰基-1,4-二氢吡啶:肿瘤细胞中的合成与多药耐药逆转
Anticancer Res. 2000 Jan-Feb;20(1A):373-7.
9
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy.药物治疗失败的炎症性肠病患者中多药耐药性(P-糖蛋白170)高表达。
Gastroenterology. 2000 Feb;118(2):279-88. doi: 10.1016/s0016-5085(00)70210-1.
10
Effects of 2,5-di-t-butyl-1,4-benzohydroquinone (BHQ) on rat aorta smooth muscle.2,5-二叔丁基-1,4-苯二酚(BHQ)对大鼠主动脉平滑肌的影响。
Eur J Pharmacol. 1998 Apr 10;346(2-3):237-43. doi: 10.1016/s0014-2999(98)00056-9.